Kathleen Burns
Nurse Practitioner · Duarte, CANPI 1750794202
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $120,249 of the $164,194 with a category attached, or 73.2%. 35 manufacturers reported payments, led by Sumitomo Pharma America, Inc. at 26.7% of the total. 2025 is the largest year on record at $50,005, 2.7 times the $18,799 reported in 2021. Among nurse practitioner clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 399 payments — averaging $411.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$44K
- Pfizer$43K
- Exelixis Inc.$29K
- Astellas Pharma US Inc$13K
- Sanofi$9K
- EMD Serono, Inc.$9K
- plus $16K from 29 others
Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
What the payments were for
- Consulting fees$6,2124%
- Speaking & faculty fees$120,24973%
- Travel & lodging$25,89716%
- Food & beverage$11,4967%
- Education$3410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 33 | $43,848 |
| Pfizer | 90 | $43,236 |
| Exelixis Inc. | 82 | $29,266 |
| Astellas Pharma US Inc | 37 | $13,270 |
| Sanofi | 19 | $9,490 |
| EMD Serono, Inc. | 16 | $9,200 |
| AVEO Pharmaceuticals, Inc. | 9 | $4,255 |
| Merck | 19 | $3,399 |
| AstraZeneca(2 entities) | 13 | $2,405 |
| Eisai Inc. | 10 | $1,997 |
| Janssen Scientific Affairs, LLC | 2 | $1,125 |
| Progenics Pharmaceuticals, Inc. | 5 | $312 |
| Johnson & Johnson | 10 | $301 |
| Dendreon Pharmaceuticals LLC | 4 | $274 |
| Sun Pharmaceutical Industries Inc. | 3 | $272 |
| Seagen Inc. | 5 | $264 |
| Bayer | 6 | $196 |
| Regeneron Healthcare Solutions, Inc. | 2 | $169 |
| AbbVie | 4 | $134 |
| Novartis | 5 | $121 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Genentech USA, Inc. | 3 | $71 |
| Teleflex LLC | 3 | $69 |
| Gilead | 2 | $63 |
| Tempus AI, Inc | 2 | $51 |
| Bristol Myers Squibb | 2 | $49 |
| Amgen | 3 | $46 |
| Mirati Therapeutics, Inc. | 1 | $45 |
| Ferring Pharmaceuticals Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Pharmaessentia USA Corporation | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Myovant Sciences Inc. | 1 | $18 |
| Incyte Corporation | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$164,194 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 115 | $1,475,744 |
| NubeqaDarolutamide | 56 | $713,384 |
| CabometyxCabozantinib S-Malate | 24 | $584,992 |
| ErleadaApalutamide | 37 | $545,285 |
| Abiraterone Acetate | 195 | $391,336 |
| OrgovyxRelugolix | 124 | $332,112 |
| Potassium Chloride | 24 | $853 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 20 | $695 |
| Prednisone | 123 | $645 |
| Bicalutamide | 12 | $499 |
| Ondansetron Hcl | 13 | $413 |
| Tamsulosin Hcl | 35 | $406 |
| Alendronate Sodium | 35 | $380 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $265 |
| Gabapentin | 20 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $13,270 | $1,475,744115 claims |
| BayerNubeqa | $196 | $713,38456 claims |
| Exelixis Inc.Cabometyx | $29,266 | $584,99224 claims |
| Johnson & JohnsonErleada | $301 | $545,28537 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,125 | $391,336195 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $43,848 | $332,112124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Duarte
- Erin KoppDuarte$107K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$884K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.